Does anyone have it down pat what repeated dosing (3 times per week) mean?
Is it dosing three days in a row; once per day?
Is it dosing at hour 0 and hour 23 on day 1;
at hour 0 and hour 23 on day 3;
at hour 0 and hour 23 on day 5
of each week?
Anyone have a good rapport with Leo when emailing him?
From the PR:
Ideally, a dosage regimen is established for each drug to provide the correct plasma level without excessive fluctuation and drug accumulation outside the therapeutic window. Kevetrin has less than a two-hour half-life. PK results indicate that with the current dose regimen Kevetrin is almost completely out of plasma within 24 hr. Therefore, little drug remains for any substantial period of time afterwards.
Based on these findings, we believe the impact of Kevetrin when administered to patients with repeated dosing (3 times per week), as planned in the upcoming ovarian cancer trial, will achieve fairly steady levels of Kevetrin above the MEC. The sustained activation/modulation of p53 will modulate multiple signaling pathways and should substantially increase its therapeutic efficacy.
Is it dosing three days in a row; once per day?
Is it dosing at hour 0 and hour 23 on day 1;
at hour 0 and hour 23 on day 3;
at hour 0 and hour 23 on day 5
of each week?
Anyone have a good rapport with Leo when emailing him?
From the PR:
Ideally, a dosage regimen is established for each drug to provide the correct plasma level without excessive fluctuation and drug accumulation outside the therapeutic window. Kevetrin has less than a two-hour half-life. PK results indicate that with the current dose regimen Kevetrin is almost completely out of plasma within 24 hr. Therefore, little drug remains for any substantial period of time afterwards.
Based on these findings, we believe the impact of Kevetrin when administered to patients with repeated dosing (3 times per week), as planned in the upcoming ovarian cancer trial, will achieve fairly steady levels of Kevetrin above the MEC. The sustained activation/modulation of p53 will modulate multiple signaling pathways and should substantially increase its therapeutic efficacy.
